The Hippo

HOME| ADVERTISING | CONTACT US|

» » »

Valcyte for Cytomegalovirus in Children Nashua NH

The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

Michael Rosenfeld, MD
(603) 880-1440
505 W Hollis St
Nashua, NH
Specialties
Pediatrics
Gender
Male
Education
Medical School: Med Coll Of Wi, Milwaukee Wi 53226
Graduation Year: 1976

Data Provided by:
Dr. Sumana Myneni
(281) 412-2355
8 Prospect St
Nashua, NH
Specialty
Pediatrics

Fitzpatrick Sean W MD
(603) 882-2921
38 Tyler Street
Nashua, NH
 
Christine FitzGerald
(603) 880-1440
505 W Hollis St
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Ranjan N Dandekar
(603) 891-4400
173 Daniel Webster Hwy
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Lila Hospon Monahan
(603) 891-0083
383 East Dunstable Road
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Valerie Atkins
(603) 577-2616
8 Prospect St
Nashua, NH
Specialty
Pediatrics, Neonatal-Perinatal Medicine

Data Provided by:
Dr. Lawrence Mark Learner
505 W Hollis St
Nashua, NH
Specialty
Pediatrics

Kaplan McNamee Pediatrics
(603) 595-7388
280 Main Street Suite 410
Nashua, NH
 
Anindita Das
(603) 886-5520
19 Tyler St
Nashua, NH
Specialty
Pediatrics

Data Provided by:
Data Provided by:

Valcyte for Cytomegalovirus in Children

Provided By:

MONDAY, Aug. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Valcyte (valganciclovir hydrochloride) to prevent cytomegalovirus (CMV) disease in children 4 months to 16 years who are undergoing kidney or heart transplant, Swiss drug maker Roche said Monday.

CMV disease is a common infection among people who have had an organ transplant. Such patients may be infected with CMV before their surgeries, or be receiving organs that are infected, Roche said in a news release. Children are at increased risk of CMV infection and serious complications when their immune systems are suppressed to prevent rejection of donor organs.

CMV infects about 80 percent of the U.S. population, the company said, and in most cases lies dormant in the body. But when the immune system is weakened, CMV complications could affect the lungs, kidneys, nervous system, liver and gastrointestinal tract -- potentially leading to serious illness or death.

As part of the approval, the FDA sanctioned a new oral liquid form of the drug to allow for easier use in children, Roche said.

The drug has not been evaluated in transplant patients under 4 months of age, the company said.

More information

The FDA has more about this drug's history.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

®2010 Hippo Press. site by wedu